Prescription du célécoxib (Célébrex®) lors de sa commercialisation : une étude conduite à partir de la base de données du régime général de l’assurance maladie de la région Aquitaine
- 1 January 2005
- Vol. 60 (1) , 25-29
- https://doi.org/10.2515/therapie:2005003
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- NSAID Use Profiles Derived from Reimbursement Data in FranceTherapies, 2004
- Differences between clinical trials and postmarketing useBritish Journal of Clinical Pharmacology, 2003
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory DrugsAnnals of Internal Medicine, 1995